dc.contributor.author | Guirguis-Blake, Janelle | eng |
dc.contributor.author | Wright, Andrew | eng |
dc.contributor.author | Rich, Joanne | eng |
dc.date.issued | 2008 | eng |
dc.description.abstract | Selective serotonin-reuptake inhibitors (SSRIs) appear to be the safest, given current data. Major safety concerns--prompting a US Food and Drug administration (FDA) black box label warning--have been raised about increased risk of suicidality (ideation, behavior, and attempts) among adolescents receiving antidepressant therapy. Information about the safety of tricyclic antidepressants in young people is limited because adverse effects have not been systematically reported in trials (SOR: A, meta-analysis). | eng |
dc.identifier.uri | http://hdl.handle.net/10355/3841 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2008 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | Journal of family practice, 57, no. 05 (May 2008): 327+ | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | selective serotonin-reuptake inhibitors (SSRIs) | eng |
dc.subject | safety concerns | eng |
dc.subject | suicide precautions | eng |
dc.subject.lcsh | Depression in adolescence | eng |
dc.subject.lcsh | Antidepressants -- Effectiveness | eng |
dc.subject.lcsh | Teenagers -- Suicidal behavior -- Prevention | eng |
dc.title | Which drugs are safest for moderate to severe depression in adolescents? | eng |
dc.type | Article | eng |